Courtagen Life Sciences, Inc. to Partner with Avaxia Biologics, Inc. in GI Acute Radiation Syndrome Initiative

WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc. (“Courtagen”), a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced that it has entered into a strategic collaboration with Avaxia Biologics, Inc. (“Avaxia”) to develop an assay that will streamline the development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The combined effort will focus on addressing the critical need to quickly and accurately identify the impact of Avaxia’s oral antibody therapy in animal models and, ultimately, in patients.